Ixoberogene soroparvovec is a gene therapy commercialized by Adverum Biotechnologies, with a leading Phase II program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 5 clinical trials, of which 1 was completed, and 4 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ixoberogene soroparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ixoberogene soroparvovec is expected to reach an annual total of $25 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ixoberogene soroparvovec Overview
ADVM-022 is under development for the treatment of wet age-related macular degeneration (wAMD, wet exudative macular degeneration). The drug candidate is a vector based anti-VEGF cDNA administered through intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). It is developed based on next generation adeno-associated virus (AAV)-based directed evolution platform. It was under development for the treatment of diabetic retinopathy including diabetic macular edema.
Adverum Biotechnologies Overview
Adverum Biotechnologies (Adverum), formerly Avalanche Biotechnologies, is a clinical-stage gene therapy provider. The company’s product pipeline includes ADVM-022 for Wet AMD and ADVM-022 for DME. Its products are used for the treatment of unmet medical needs in ocular and rare diseases. Adverum’s ADVM-022 is a single, in-office intravitreal (“IVT”) injection gene therapy that improves the real-world vision outcomes for patients. The company collaborates with academic institutions and pharmaceutical companies. It also offers research and development, pre-clinical services, and manufacturing services. The company operates in the US, the UK, and France. Adverum is headquartered in Redwood City, California, the US.
The company reported revenues of (US Dollars) US$7.5 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$146.1 million in FY2021, compared to an operating loss of US$118 million in FY2020. The net loss of the company was US$145.5 million in FY2021, compared to a net loss of US$117.5 million in FY2020.
For a complete picture of Ixoberogene soroparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.